Biomarkers identifying hepatic inflammation in non-alcoholic fatty liver disease (NAFLD)

被引：0
|
作者：
Werge, Mikkel [1 ]
Hoegl, Annabelle [2 ]
Therkelsen, Marie Louise [2 ]
Gronborg, Mads [2 ]
Mazzoni, Gianluca [2 ]
Harder, Lea Morch [2 ]
Hvid, Henning [2 ]
Rashu, Elias [1 ]
Thing, Mira [1 ]
Hetland, Liv [1 ]
Junker, Anders [1 ]
Serizawa, Reza [3 ]
Vyberg, Mogens [3 ,4 ]
Galsgaard, Elisabeth [2 ]
Gluud, Lise Lotte [5 ]
机构：
[1] Copenhagen Univ Hosp Hvidovre, Gastro Unit, Hvidovre, Denmark
[2] Novo Nordisk AS, Res & Early Dev, Malov, Denmark
[3] Copenhagen Univ Hosp Hvidovre, Pathol, Hvidovre, Denmark
[4] Aalborg Univ, Ctr RNA Med, Copenhagen SV, Denmark
[5] Univ Copenhagen, Med Clin, Copenhagen N, Denmark
来源：
JOURNAL OF HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
WED-411
引用
收藏
页码：S742 / S743
页数：2
相关论文
共 50 条
  • [41] Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
    Yip, Terry Cheuk-Fung
    Lyu, Fei
    Lin, Huapeng
    Li, Guanlin
    Yuen, Pong-Chi
    Wong, Vincent Wai-Sun
    Wong, Grace Lai-Hung
    CLINICAL AND MOLECULAR HEPATOLOGY, 2023, 29 : S171 - S183
  • [42] Fatty Liver Index (FLI) in Predicting Non-alcoholic Fatty Liver Disease (NAFLD)
    Dehnavi, Zahra
    Razmpour, Farkhonde
    Naseri, Mahmoud Belghaisi
    Nematy, Mohsen
    Alamdaran, Seyed Ali
    Vatanparast, Hassan Ali
    Nezhad, Mohsen Azimi
    Abbasi, Bita
    Ganji, Azita
    HEPATITIS MONTHLY, 2018, 18 (02)
  • [43] Non-alcoholic fatty liver disease-A pilot study investigating early inflammatory and fibrotic biomarkers of NAFLD with alcoholic liver disease
    Watt, Joanne
    Kurth, Mary Jo
    Reid, Cherith N. N.
    Lamont, John V. V.
    Fitzgerald, Peter
    Ruddock, Mark W. W.
    FRONTIERS IN PHYSIOLOGY, 2022, 13
  • [44] Hepatic expression of leptin in patients of non-alcoholic fatty liver diseases (NAFLD)
    Okumura, K
    Ikejima, K
    Matsumoto, S
    Yamashina, S
    Fukuda, T
    Enomoto, N
    Suzuki, S
    Kitamura, T
    Takei, Y
    Sato, N
    GASTROENTEROLOGY, 2004, 126 (04) : A756 - A756
  • [45] Sevelamer improves hepatic steatosis and modulates inflammation in a Western Diet mouse model of non-alcoholic fatty liver disease (NAFLD)
    McGettigan, Brett
    McMahan, Rachel
    Porsche, Cara
    Orlicky, David J.
    Wang, Xiaoxin
    Luo, Yuhuan
    Levi, Moshe
    Rosen, Hugo R.
    HEPATOLOGY, 2014, 60 : 746A - 747A
  • [46] Controlled Attenuation Parameter (CAP) for the detection of hepatic steatosis in alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD)
    Naveau, Sylvie
    Perlemuter, Gabriel
    Ziol, Marianne
    Carmona, Damien
    Trinchet, Jean Claude
    Prevot, Sophie
    Nohra, Pascal
    Nguefang-Njike, Micheline Nakseu
    Beaugrand, Michel
    HEPATOLOGY, 2012, 56 : 898A - 898A
  • [47] Leptin as a marker of liver fibrosis in non-alcoholic fatty liver disease (NAFLD)
    Petrovic, LM
    Alba, LM
    Lindor, KD
    Talwakar, JA
    Angulo, P
    LABORATORY INVESTIGATION, 2003, 83 (01) : 283A - 283A
  • [48] Leptin as a marker of liver fibrosis in non-alcoholic fatty liver disease (NAFLD)
    Petrovic, LM
    Alba, LM
    Lindor, KD
    Talwakar, JA
    Angulo, P
    MODERN PATHOLOGY, 2003, 16 (01) : 283A - 283A
  • [49] Liver Biopsy and Non-alcoholic Fatty Liver Disease (NAFLD) in Bariatric Patients
    Kanakala, V.
    Chattopadhyay, D.
    Sarkar, R.
    Balupuri, S.
    Small, P. K.
    BRITISH JOURNAL OF SURGERY, 2015, 102 : 285 - 285
  • [50] Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease
    Shinozaki, Satoshi
    Tahara, Toshiyuki
    Lefor, Alan Kawarai
    Ogura, Masahito
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2020, 6 (03) : 270 - 274
12345